MED Rallies 13.6% in the Past Month: Can the Momentum Keep Building?

Medifast, Inc. MED shares have gained 13.6% in the past month compared with the industry's 3.5% growth, bringing the sustainability of that move into focus. The stock's next leg may depend on whether improving operating indicators translate into a firmer business trend.

Image Source: Zacks Investment Research

Coach productivity and earnings expectations are moving in a better direction. Revenue and the size of the active coach base, however, remain under pressure.

MED's 13.5% Monthly Gain Needs Fundamental Support

The recent rally comes against a mixed operating backdrop. Second-quarter 2026 revenues were $76.4 million, down from $105.6 million a year earlier, as fewer active earning coaches continued to weigh on the business.

The sequential picture is steadier. Management said revenues have stabilized around the mid-$70 million level in recent quarters and maintained full-year revenue guidance of $270 million to $300 million. That stability offers some support for the stock's momentum, but a durable recovery still requires improvement in the underlying sales engine.

MED's Earnings Surprise Adds to the Momentum Case

Medifast reported a second-quarter loss of 28 cents per share, substantially narrower than the consensus loss of 67 cents. Revenues also came in slightly above expectations, giving investors a better-than-feared quarterly result even as year-over-year sales remained weak.

MEDIFAST INC Price, Consensus and EPS Surprise

MEDIFAST INC price-consensus-eps-surprise-chart | MEDIFAST INC Quote

Estimate revisions add another constructive signal. The fiscal-year earnings estimate has moved 49.2% higher over the past four weeks. Rising earnings expectations can support price momentum when investors see a better path for profitability, although the company still expects a loss for 2026.

Medifast's Coach Productivity Is Improving

Average revenue per active earning coach increased 41% year over year to $6,529 in the second quarter and rose 20% sequentially. That marked the third consecutive quarter of year-over-year productivity growth and the highest level since the second quarter of 2022.

Management views productivity as an early indicator because stronger coach output has historically preceded better client acquisition, coach growth and revenue expansion. The company expects productivity to continue improving through 2026, helped by its focus on more productive coach organizations and the rollout of Trilivy-related initiatives.

MED Still Faces a Shrinking Coach Base

The main constraint remains the size of Medifast's network. Active earning coaches fell 48.7% year over year to 11,700, and the company expects the count to continue declining during 2026 despite anticipating growth in new coach additions in the second half.

Among consumer-staples peers, Mama's Creations, Inc. MAMA operates in prepared foods, while US Foods Holding Corp. USFD is a foodservice distributor. Both offer a broader sector comparison for Medifast, though their operating models differ from MED's coach-led metabolic-health business.

MED's Momentum Score Supports a Mixed Setup

The stock currently carries a Zacks Rank #3 (Hold) and a Momentum Score of A. The favorable Momentum Score indicates that MED screens well on momentum characteristics, which fits with the recent share-price advance. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here. 

The broader Style Score picture is less supportive. MED has a Value Score of D, Growth Score of F and VGM Score of D. Since Style Scores are designed to complement the Zacks Rank, that combination points to a mixed setup rather than an across-the-board positive signal. Continued productivity gains, firmer revenues and progress toward profitability would be important for sustaining the recent momentum.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research